The effect of oral probiotics on glycemic control of women with gestational diabetes mellitus - multicenter, randomized, double blind, placebo controlled trial.
gestational diabetes mellitus
glycemic control
pregnancy
pregnancy outcomes
probiotics
Journal
American journal of obstetrics & gynecology MFM
ISSN: 2589-9333
Titre abrégé: Am J Obstet Gynecol MFM
Pays: United States
ID NLM: 101746609
Informations de publication
Date de publication:
11 Nov 2023
11 Nov 2023
Historique:
received:
17
10
2023
revised:
29
10
2023
accepted:
08
11
2023
medline:
14
11
2023
pubmed:
14
11
2023
entrez:
13
11
2023
Statut:
aheadofprint
Résumé
Gestational diabetes mellitus (GDM) should be treated adequately in order to avoid maternal hyperglycemia-related complications. Previously, probiotic supplements were suggested to improve fasting blood glucose in women with GDM. Yet, a major limitation of previous studies was that pre-prandial and especially post-prandial glucose values, which are important predictors of pregnancy outcomes, were not studied. To examine the effect of a mixture of probiotic strains on maternal glycemic parameters, particularly pre-prandial and postprandial glucose values and pregnancy outcomes among women with GDM. A multicenter prospective randomized, double blind, placebo controlled trial was conducted. Women newly diagnosed with GDM were randomly allocated into a research group, receiving two capsules of oral probiotic formula containing Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus (L) acidophilus, L. paracasei, L. rhamnosus and Streptococcus thermophilus (>6 × 10 Forty one and 44 women were analyzed in the treatment and placebo cohorts, respectively. Mean daily glucose during the first two weeks in the probiotics and placebo groups was 99.7±7.9 and 98.0±9.3 mg/dL, respectively; P=0.35. The rate of women needing pharmacotherapy due to poor glycemic control after two weeks of treatment in the probiotics and placebo groups was 24 (59%) and 18 (41%), respectively; P=0.10. Mean, pre-prandial and post-prandial glucose levels throughout the study period were similar between the groups (P>0.05). There were no differences in maternal and neonatal outcomes including birth weight and adverse effect profile between the groups. The oral probiotic product tested in this study did not affect glycemic control of women with GDM.
Sections du résumé
BACKGROUND
BACKGROUND
Gestational diabetes mellitus (GDM) should be treated adequately in order to avoid maternal hyperglycemia-related complications. Previously, probiotic supplements were suggested to improve fasting blood glucose in women with GDM. Yet, a major limitation of previous studies was that pre-prandial and especially post-prandial glucose values, which are important predictors of pregnancy outcomes, were not studied.
OBJECTIVE
OBJECTIVE
To examine the effect of a mixture of probiotic strains on maternal glycemic parameters, particularly pre-prandial and postprandial glucose values and pregnancy outcomes among women with GDM.
STUDY DESIGN
METHODS
A multicenter prospective randomized, double blind, placebo controlled trial was conducted. Women newly diagnosed with GDM were randomly allocated into a research group, receiving two capsules of oral probiotic formula containing Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus (L) acidophilus, L. paracasei, L. rhamnosus and Streptococcus thermophilus (>6 × 10
RESULTS
RESULTS
Forty one and 44 women were analyzed in the treatment and placebo cohorts, respectively. Mean daily glucose during the first two weeks in the probiotics and placebo groups was 99.7±7.9 and 98.0±9.3 mg/dL, respectively; P=0.35. The rate of women needing pharmacotherapy due to poor glycemic control after two weeks of treatment in the probiotics and placebo groups was 24 (59%) and 18 (41%), respectively; P=0.10. Mean, pre-prandial and post-prandial glucose levels throughout the study period were similar between the groups (P>0.05). There were no differences in maternal and neonatal outcomes including birth weight and adverse effect profile between the groups.
CONCLUSION
CONCLUSIONS
The oral probiotic product tested in this study did not affect glycemic control of women with GDM.
Identifiants
pubmed: 37956906
pii: S2589-9333(23)00366-X
doi: 10.1016/j.ajogmf.2023.101224
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
101224Informations de copyright
Copyright © 2023. Published by Elsevier Inc.